Investing.com - Financial Markets Worldwide

Intel, Johnson & Johnson and Boeing rise premarket; Wayfair falls

AuthorPeter Nurse
Published 26/09/2025, 11:56
© Reuters
BA
0.50%
INTC
0.46%
LLY
-2.02%
COST
1.16%
PFE
1.16%
JNJ
0.57%
META
0.68%
W
-1.05%
APLS
1.53%
XPEV
-0.80%
CNXC
-0.04%
GFS
0.06%

Investing.com -- U.S. stock futures traded in a stable manner Friday, as investors digested the new trade tariffs from the Trump administration ahead of key inflation data.

Here are some of the biggest premarket U.S. stock movers today:

  • Intel (NASDAQ:INTC) stock gained 3.7% and GlobalFoundries (NASDAQ:GFS) rose 9.9% after the Wall Street Journal reported the Trump administration is weighing options to substantially lower America’s reliance on semiconductor imports by boosting local manufacturing.

  • Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE) and Eli Lilly (NYSE:LLY) all rose after U.S. President Donald Trump announced fresh 100% tariffs on imports of branded pharmaceuticals.

  • Wayfair (NYSE:W) stock slipped 3.5% and Bed Bath & Beyond dropped 1.8%, with furniture companies hit by Trump’s announcement of tariffs on kitchen cabinets and upholstered furniture.

  • Boeing (NYSE:BA) stock rose 0.7% after both Norwegian Air and Turkish Airlines agreed to purchase more planes from the U.S. aircraft manufacturer.

  • Meta Platforms (NASDAQ:META) rose 0.3% after the tech giant said it would offer an ad-free subscription option to Facebook and Instagram users in the United Kingdom in the coming weeks.

  • Costco (NASDAQ:COST) stock fell 0.6% despite the warehouse retailer impressing with its fourth quarter earnings, helped by its new global locations, digital upgrades and the impact of its expanded hours for executive members.

  • Concentrix (NASDAQ:CNXC) stock slumped 19% after the call-center operator missed its quarterly earnings expectations and lowered its full-year forecast.

  • Xpeng (NYSE:XPEV) stock rose 4.2% after Morgan Stanley added the Chinese electric-vehicle maker to its key focus lists, highlighting its strong model pipeline and positioning as a leading AI adopter.

  • Apellis Pharmaceuticals (NASDAQ:APLS) stock fell 9.5% after Goldman Sachs downgraded its rating on the clinical-stage biopharmaceutical company to “sell” from “neutral”, citing concerns about the growth trajectory of the company’s geographic atrophy treatment Syfovre.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.